C
Caraway
Biotech & Life Sciences · Cambridge, United States · Founded 2018
invent novel treatments for neurodegenerative disease through modulation of mitophagy and autophagy MoreLess
Caraway Therapeutics is an emerging biopharmaceutical company focused on developing novel treatments for debilitating neurodegenerative diseases. The company is pioneering the use of cellular recycling processes, known as autophagy, to clear toxic materials and defective cellular components from neurons. This innovative approach aims to preserve neuron function and slow disease progression. Caraway Therapeutics primarily serves patients suffering from neurodegenerative conditions, a market characterized by high unmet medical needs and significant demand for effective therapies. The company's business model revolves around rigorous scientific research and development, leveraging genetically defined targets to identify potential therapeutic candidates. Revenue is generated through research grants, partnerships, and eventual commercialization of successful treatments.
Keywords: neurodegenerative diseases, neuron preservation, cellular recycling, autophagy, biopharmaceutical, innovative treatments, scientific research, genetically defined targets, therapeutic candidates, high unmet medical needs.
Company overview
Caraway company information
The essential company record, classifications and operating signals in one place.
- Status
- Acquired
- Founded
- 2018
- Headquarters
- Cambridge, United States
- Employees
- 4
- Open positions
- None listed
- Dealroom signal
- 25.0
Valuation & funding
Caraway funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| ACQUISITION✓Exit | Nov 2023 | $610M | $610M | Merck & Co. | ↗ |
| SERIES A✓Equity / VC | Nov 2018 | $23M | $92M | Mayo Clinic · Abbvie Biotech Ventures · MRL Ventures · Amgen Ventures | ↗ |
Financials
Workforce over time
Available workforce history. Financial fields without reported data are omitted.
| Year | Employees |
|---|---|
| 2026 | 4 |
| 2025 | 23 |
| 2024 | 23 |
| 2023 | 23 |
Growth signals
Caraway website traffic
Latest recorded traffic for Caraway is 280 monthly website visits, down 54.1% over the last three months. Caraway's team declined 82.6% over the past year.
Comparisons
Caraway compared with similar companies
Dealroom’s weighted taxonomy model identifies the closest operating peers. Company identity and context stay open; selected comparison metrics preview what is available in the platform.
Talent graph
Caraway's talent
Source: Dealroom Talent Intelligence.
Investors
7 investors on Caraway's cap table
Sourced from Dealroom's funding and investor records.
Global footprint
Where Caraway has talent and traffic
In the news
Latest news about Caraway
Recent press, funding announcements, and product moves mentioning Caraway — open to read from the original sources.
Market sentiment
What the market is saying about Caraway
An AI-synthesized read of the highest-engagement posts about Caraway on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Caraway’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.